Skip to content

Altis Biosystems

2 viewers · 30d

Total raised

$2.1M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $2.1M
ROUNDS
1
INVESTORS
9
FOUNDED
N/A
HQ
Durham, NC
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Altis Biosystems, Inc. is a pioneering biotechnology firm based in North Carolina, dedicated to enhancing preclinical research through the development of innovative human cell-based models that accurately replicate the gastrointestinal (GI) tract. By providing superior alternatives to traditional cell line and animal models, Altis facilitates improved drug discovery and development, ensuring better predictive insights and reducing reliance on animal testing.

What sets it apart

The company stands out by offering a unique biobank of stem cells from diverse human donors, allowing for highly customizable research that addresses patient-specific treatment variations.

Funding history

1 round
EquityMar 31, 2025
Form D
+$2.1M$2.1M total

Latest SEC filings

via EDGAR · CIK 0001799892
Form D · Mar 31, 2025View on EDGAR

Products

1 tracked

RepliGut® System

In Vitro Models

The RepliGut® System is a groundbreaking collection of in vitro models derived from human intestinal stem cells that replicate the structure and function of the human intestine. It is designed to advance preclinical research by providing more human-relevant data for drug efficacy, toxicity, and bioavailability assessments.

  • RepliGut® Planar for drug-induced toxicity and permeability assays
  • RepliGut® Crypt to model intestinal crypt cell development
  • RepliGut® Kits for customized experimental setup with essential materials included

Links

WebsiteSEC EDGAR filings